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Abstract
Nitric oxide (NO) is an endogenic product from plants, bacteria, and animal cells that 
has many important effects in those organisms. It is produced by nitric oxide synthase 
(NOS), which is found in main three isoforms, namely endothelial NOS (eNOS), induc-
ible NOS (iNOS), and neuronal NOS (nNOS). It has an important role in homeostasis in 
different physiological systems, such as micro- and macro-vascularization, inhibition of 
platelet aggregation, and neurotransmission regulation in the central nervous, gastroin-
testinal, respiratory, and genitourinary systems. However, its overproduction has been 
associated with diseases such as arthritis, asthma, cerebral ischemia, Parkinson’s disease, 
neurodegeneration, and seizures. For this reason, and due to better understanding of the 
molecular mechanisms by which NO provokes those diseases, the interest on the design 
of NOS inhibitors with therapeutic purposes has highly increased. Based on the forego-
ing considerations, the proposal of this chapter is to show an overview about the design 
strategies, mechanism of action at the molecular level, and the main advances toward the 
search for selective NOS inhibitors available in the literature.
Keywords: nitric oxide synthase isoforms, structure-based drug design, enzymatic 
inhibition, selectivity, heterocyclic compounds
1. Introduction
Nitric oxide (NO) is a diatomic neutral molecule, produced by bacteria, plants, and animals. 
Having one unpaired electron, its effect in biological system is related to the stabilization of 
this electron. It acts as dissolved nonelectrolyte in the organisms, except for the lungs, where 
it is found in gaseous state [1–3].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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distribution, and reproduction in any medium, provided the original work is properly cited.
NO has gain importance mainly in the 1990s, and from then on, it has been studied to obtain 
interesting pharmacological effects. A review by Serafim and collaborators describes the state 
of the art of this compound use in drug design [4].
The basal NO production has an important contribution to homeostasis in different physi-
ological systems, such as micro- and macro-vascularization, inhibition of platelet aggrega-
tion, and neurotransmission regulation in central nervous, gastrointestinal, respiratory, and 
genitourinary systems. However, NO overproduction has been strongly associated with some 
diseases such as arthritis, asthma, cerebral ischemia, Parkinson’s disease, neurodegeneration, 
and seizures [5–9].
Nitric oxide synthase (NOS) is the enzyme responsible for NO biosynthesis, and there are 
three main kinds of NOS isoforms [endothelial NOS (eNOS), inducible NOS (iNOS), and 
neuronal NOS (nNOS)]. They are tetramers, constituted of two NOS monomers associated 
with two calmodulin monomers (CaM), and contain relatively tightly bound cofactors, BH
4
, 
FAD, FMN, and iron protoporphyrin IX (heme group). Their chemical function is to catalyze 
the reaction of l-arginine, NADPH, and oxygen to synthesize free radical NO, l-citrulline, 
and NADP (Figure 1) [10].
The substrate l-arginine establishes H-bond networks inside the catalytic site of NOS iso-
forms with the heme group, mainly due to the guanidine group, which is crucial to bind 
tightly using a salt-bridge interaction with the conserved carboxylate of Glu597 in human 
nNOS, Glu377 for iNOS and Glu361 for eNOS. In addition, l-arginine establishes H-bonds 
with the amide carbonyl from Trp592, in nNOS; with Trp372, in iNOS; and with Trp356, 
in eNOS. Moreover, α-amino group of l-arginine interacts through H-bond with the heme 
propionate side chain, and the guanidine N-terminal nitrogen of this amino acid coordinates 
with FeII (Figure 2). This ligand-receptor interaction profile is similar to all isoforms, which 
generates a challenge to selectivity [11].
 Figure 1. General reaction of NO formation by NOS. Adapted from [10].
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Exacerbated induction of iNOS is associated with septic shock, inflammatory, and noninflam-
matory impairment processes in different tissues/organs, and, likewise, the nNOS is triggered 
in neurotoxicity, neurodegeneration process, and proliferation increase of some neoplastic 
cell lines. Depending on the clinical condition, decreasing NO levels is necessary, and excel-
lent benefits might be achieved using NOS inhibitors. However, it is much important not to 
inhibit eNOS, because of its central role in smooth muscle relax, controlling vascular tone and 
blood pressure [12–14].
The first inhibitors designed (during the1980s and early 1990s) were based on l-arginine, the 
substrate of the enzyme, and this approach led to potent compounds but with poor selectiv-
ity level among the isoforms. In the late 1990s, the first crystal structure of iNOS and eNOS 
was unveiled, showing the high degree of similarity particularly in the active site of both 
isoforms. The nNOS crystal structure was reported in 2002, allowing the design of selective 
inhibitors [15, 16]. It is worth noting that changes in some amino acids of the isoforms lead 
to differences in electronic and steric effects on the binding site region, which can be inter-
esting for designing selective inhibitors [11, 15]. The active collaboration between Richard 
Silverman and Thomas Poulos’ groups has significantly contributed to this field, and some of 
their papers are discussed in this chapter.
 Figure 2. Scheme of nNOS-binding site.
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NOS isoforms were validated as target for new drugs soon after their X-ray crystallogra-
phy was available. From then on the design of effective and selective inhibitors has been an 
important approach in modern drug discovery involving NO biochemical pathways related 
to many dysfunctions of the human organism [12, 17–19].
2. Experimental studies
2.1. Inducible nitric oxide synthase (iNOS) inhibitors
Garvey and collaborators (1994) were the first to report highly selective iNOS inhibitors. The 
compounds were isothiourea derivatives (Figure 3—1) designed as l-arginine-competitive 
reversible inhibitors of human iNOS, with a K
i
 = 47 nM and a 190-fold selectivity over eNOS 
but only ~5-fold over nNOS [10, 20]. Further studies of the group led to the design of com-
pound 1400W (Figure 3), which is highly selective over eNOS and nNOS and able to penetrate 
into cells and tissues [10, 21].
The selective iNOS inhibition by aminoguanidine (Figure 3—AG) showed that NO can medi-
ate the disruption of hematopoiesis during acute graft-versus-host disease (GVHD), also 
decreasing the endogenous bacterial infections in the spleen and liver in mice receiving the 
inhibitor [22]. The deleterious neuro-inflammation effects of iNOS/NO system stimulated by 
lipopolysaccharide (LPS) on learning and memory were evaluated in rats. Aminoguanidine 
decreases TNFα levels, oxidative stress indicators, and NO metabolites [23]. In addition, this 
compound seems to significantly relieve periapical inflammation in the canine teeth of cats 
and to reduce histological multiple organ damage in rats [24, 25].
 Figure 3. iNOS inhibitors (part 1).
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In 2000, Hagmann and collaborators explored the structure-activity relationships of a series of 
substituted 2-aminopyridines. Compounds 4,6-dialkyl substituted (Figure 3—2 and 3) were 
found to be the most potent inhibitors of iNOS, presenting a significant degree of selectivity for 
this isoform [26]. Exploring the same scaffold, the synthesis of the derivatives N-4-piperidinyl-
2-aminopyridine led to compound 4 (Figure 3), a 4-methoxy substituted derivative, 4-fold 
more potent in iNOS inhibition compared to the 4-methyl compound. Moreover, 4-cyano-
benzamide derivative (Figure 3—AR-C133057XX) presented IC
50
 = 0.071 μM, being 1400-fold 
and around 100-fold selective for eNOS and nNOS, respectively. X-ray crystallography of 
AR-C133057XX showed that pyridine moiety binds deeply to the heme pocket, while the exo-
cyclic ring interacts with another binding pocket. This difference in interaction could explain 
the good selectivity of this molecule [27].
On the other hand, the 1,2-dihydro-4-quinazolinamine compound AR-C102222 (Figure 3) 
showed a dose-dependent inhibition on NO production induced by lipopolysaccharide (LPS). 
At the highest dose tested (100 μmol/kg) in rats, this compound completely abolished the 
chronic inflammatory arthritis development all over the 20-day experiment, thus confirming 
the in vivo efficacy of the class [28].
Structural-based approach using crystal structure and mutagenesis have identified specific 
induced-fit binding mode, which can generate some conformational changes toward a new 
specific cavity. Garcin and coworkers showed the cis-amidine moiety of quinazoline and 
aminopyridine chemotypes in the compounds AR-C133057XX and AR-C102222, respec-
tively, promoted interactions of hydrogen with Glu (Glu371 and Glu377, mouse and human, 
respectively) at the binding site and with the heme group (mimicking the l-arginine sub-
strate) (Figure 4). Those interactions increased the affinity of the inhibitor-containing bulky 
groups for iNOS. This occurs when Gln rotates on its own axis, accommodating the rigid 
bulky moieties of the inhibitors and exposing a new specific pocket to interact. The Gln-open 
conformation can create a cascade of conformational changes, leading to the generation of 
this new interaction site and directing the selectivity to the aminopyridine and quinazoline 
scaffolds [29]. Quantitative structure-activity relationships (QSAR) of quinazoline derivatives 
have been performed to evaluate the structural features required to interact with the active 
site of iNOS, allowing the design of more effective inhibitors [30].
 Figure 4. (A) iNOS-binding profile of AR-C133057XX, PDB code: 3EAI; (B) iNOS-binding profile of AR-C102222, PDB 
code: 3E7T.
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Other compounds, as acetamidine derivatives (Figure 5—5 and 6), designed to inhibit iNOS, 
showed submicromolar activities (IC
50
 = 0.428 and 0.165 μM, respectively) and excellent selec-
tivity over eNOS (>2300 and 550-fold more selective, respectively). In silico findings revealed 
that the activity drastically changes when ending amino groups are located instead of carbox-
ylic function in the acceptor H-bond region, which is adjacent to the lipophilic region. This 
occurs because the charged amino group and its alkyl chain are not able to be stabilized inside 
the pocket interaction region of the enzyme, decreasing the binding efficiency [31].
A protein called SPSB2 plays an important role in modulating the activity of iNOS through its 
proteasomal degradation in defense cells. Since this complex is blocked, the NO production 
from iNOS is prolonged, increasing the killing activity against pathogen microorganisms, 
making it an interesting anti-infective target [32]. Some cyclic peptidomimetic compounds 
were designed using this strategy, and the most potent compound 7 (Figure 5) showed 
strong inhibition of SPSB2-iNOS complex in macrophage cell lysates and potent affinity value 
(K
D
 = 29 nM) [33].
High-throughput screening (HTS) strategy has been used to identify new iNOS inhibitors hits 
such as the compound 8 (Figure 5). After structural optimization process, the quinolone amide 
derivative 9 (Figure 5) was generated. This derivative has 2000-fold selectivity over human 
eNOS, besides being very potent (iNOS IC
50
 = 11 nM) and presenting oral bioavailability in 
mouse although its clearance (Clp > 100 mL/min/kg) has shown to be uninteresting [34]. The 
efforts to overcome this effect was to improve the pharmacokinetic properties, leading to the 
compound 10 (Figure 5), a 4,7-imidazopyrazine derivative. This is a dual iNOS/nNOS inhibi-
tor, showing high potency in human iNOS (IC
50
 = 0.091 μM) and activity over nNOS (0.30 μM) 
while maintaining the desired selectivity over eNOS (180-fold). Its mechanism of action at 
molecular level is based on the inhibition of the iNOS dimerization process. Furthermore, com-
pound 10 was effective using in vivo models of neuropathic pain, presenting desired clearance 
value (4–9 mL/min/kg), good oral bioavailability, and no tolerance after repeated doses [35].
Phenylpyrroles, pyrazoles, urea kynurenamines, ethynylcyanodienones, and amidine deriva-
tives (Figure 6—11, 12, 13, 14, and 15) have also been interesting scaffolds to generate iNOS 
inhibitors [36–40]. The first derivative reduced significantly the iNOS activity to control 
 Figure 5. iNOS inhibitors (part 2).
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 values in MPTP-Parkinson`s disease model, showing a potential to act in central nervous 
system (CNS) disorders [36].
Natural products have been a rich source of new bioactive molecules. Some examples in the 
NOS inhibition are a sesquiterpenoid, isolated from Curcuma wenyujin (Figure 6—16) and its 
isomer. They were strong inhibitors of NO production by LPS in iNOS (IC
50
 = 7.6 and 8.5 μM, 
respectively). Anmindenols A and B (Figure 6—17 and 18), from marine-derived bacterium 
Streptomyces sp., also demonstrated a relevant inhibitory activity in macrophage cells NO 
production (IC
50
 = 23 and 19 μM, respectively) [41, 42].
2.2. Neuronal nitric oxide synthase (nNOS) inhibitors
In the beginning of the 1990s, efforts to design selective nNOS inhibitor compounds were 
addressed, using the substrate l-arginine as the prototype molecule. Series of analogs was 
synthesized to evaluate which molecular change could interfere in the ligand activity and 
selectivity over other isoforms. The first selective compound over nNOS was l-nitroarginine 
(Figure 7), producing hypertension in animals due to the lack of selectivity over eNOS. In 
addition, many peptide analogs were synthesized trying to obtain more promising com-
pounds. After the X-ray crystal complex elucidation, structure-activity relationship findings 
of several scaffolds have been explored to identify the molecular basis of improving the selec-
tivity toward neuronal isoform [15, 19].
The non-arginine-based compound 7-nitroindazole (Figure 7—NI) showed little nNOS in 
vitro selectivity but high in vivo selectivity. Its mechanism of action involves competitive inhi-
bition of H
4
B cofactor, and series of related structures have been designed [11]. This compound 
has suppressed open-field behavior expressed as distance moved, exploratory rearing and 
grooming, suggesting that this compound can increase cortical excitability and interfere with 
some physiological and behavioral parameters [43]. Nevertheless, its  anticonvulsant activity 
 Figure 6. iNOS inhibitors (part 3).
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should be better understood, since studies in rodents reveal a beneficial activity although 
proconvulsant effect can be found in kainite-, nicotine- and soman-induced convulsions [44].
Entrena and collaborators, by using kynurenamine scaffold (Figure 7—19) as a template, car-
ried out the synthesis of a series of new candidates to neuroprotective compounds, showing 
a pharmacophore model to interact with nNOS catalytic site [45].
N-Substituted acetamidines (Figure 7—20 and 21) showed nNOS inhibition activity (IC
50
 = 0.2 
and 0.3 μM) with good selectivity index (500 and 1166-fold selectivity over eNOS, respec-
tively, and 50 and 100-fold, over iNOS, respectively). In silico studies were useful to under-
stand the fit of these scaffolds inside the catalytic site. nNOS contains a bigger heme group 
cavity compared with other isoforms, which could explain why bulky groups better accom-
modate in the neuronal isoform [46].
Aminopyridine is an attractive pharmacophoric group to bind in different regions of nNOS 
through H-bond. Using this moiety, compound 22 (Figure 7) and its optical isomer showed 
to be selective against nNOS, although unable to penetrate the blood-brain-barrier (BBB) in in 
vivo studies [15, 47, 48]. Trying to increase the CNS permeability, prodrug design approach 
was used in primary and secondary amines. However, this strategy did not increase the BBB 
penetration, even masking the charge by carbamate and azide functions [49]. On the other 
hand, using these compounds containing basic nitrogen, Xue and coworkers attached elec-
tron-withdrawing groups (Figure 7—23) close to these amine functions, decreasing their pKa 
values and improving the membrane permeability in cell-based assays [50].
Concerning 4,5-dihydro-1-H-pyrazole derivatives, they were confirmed as selective nNOS 
inhibitors. Compound 24 (Figure 7), the most active of the derivatives (82% of inhibition), 
 Figure 7. nNOS inhibitors (part 1).
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showed that its methoxy electron-donating group is important to improve potency and selec-
tivity. By molecular modeling, it was possible to identify that the phenyl moiety can fit below 
the heme group, establishing π-π interaction. The methoxy groups adopt a conformation that 
allows them to interact with Arg481 by H-bonds. Moreover, the amine group interacts by 
H-bond with one of the carboxylate moieties of the heme group. On the contrary, electron-
withdrawing groups are better to generate inhibitors for iNOS [51].
Other interesting structures such as 2-aminoquinolines are effective scaffold to be included 
in the structure of nNOS inhibitors. Crystallography studies showed that those compounds 
act as competitive arginine mimics. This scaffold makes important H-bonds with the active-
site Glu residue, and the non-coordinating aryl rings are stabilized in a hydrophobic pocket 
in the extremity of the substrate access channel. Moreover, this structural class showed good 
pharmacokinetic properties (Figure 8—25), such as brain penetration and oral bioavailability 
according to the permeability results in Caco-2 cell assay [52]. Trying to optimize this class 
of compounds, chlorine was added on the phenyl ether central aryl ring (Figure 8—26). This 
substitution was found to be selective and highly potent in the design of nNOS inhibitors 
while retaining CNS penetration and showing a diminished off-target interaction. In complex 
with human nNOS, this compound showed a phenyl ring orientation where the alkyl amine 
makes an H-bond with the H
4
B site [53].
Exploring the heme-coordinating potential of imidazole group, a series of 2,4-disubtituted 
pyrimidine compounds (Figure 8—27) was designed. They presented a nanomolar affinity to 
both rat and human nNOS (>200-fold and >100-fold selectivity over eNOS and iNOS, respec-
tively), exhibiting a minimal off-target binding to 50 CNS receptors. Crystal structures of the 
complex (nNOS-27) indicate that heme Fe coordinates by the 2-imidazolyl group, and the 
non-coordinating aryl rings are stabilized in a hydrophobic pocket at the far end of the sub-
strate access channel. The fluorine atom in compound 27 also interacts into the hydrophobic 
 Figure 8. nNOS inhibitors (part 2).
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pocket, and the secondary amine of this derivative establishes dual ionic interaction with 
both heme propionates (Figure 9). This molecular interaction profile is important to obtain 
potency and selectivity. In addition, nitrogen from pyrimidine ring performs an H-bond 
with the His342 side chain. The imidazole ring of the most active compound acts as a weak 
CYP3A4 inhibitor, suggesting that modulating hydrophobicity and bulkiness can be useful to 
attenuate the effects in CYP isoforms [54].
Studies using aminopyridine-based scaffold with pyridine linker (Figure 8—28) showed that 
difference in the position of an amino acid, Asp597 of nNOS versus Asn368 of eNOS, controls 
the affinity and binding mode of this class of nNOS inhibitors. While the central pyridine is 
at least partially protonated to points up toward Tyr562 for optimal electrostatic interactions, 
the Asp597 provides additional and important electrostatic stabilization to the other part of 
the inhibitor [55–57].
Rational strategy for identifying new nNOS inhibitors using a combination of virtual screen-
ing approach based on 3D pharmacophore model and molecular docking was able to identify 
a hit compound structurally different from the available inhibitors (Figure 8—29). This strat-
egy can be useful to design novel optimized analogs [58].
 Figure 9. Rat nNOS-binding profile of 27, PDB code: 4V3X.
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2.2.1. Double-headed nNOS inhibitors
Double-headed compounds have been explored by researches with the aim of obtaining high 
affinity binding in nNOS. Attaching a double-headed aminopyridine moiety in a compound 
led to a very potent (K
i
 = 25 nM) and selective (107-fold selective over nNOS and eNOS) com-
pound (Figure 10—30). Both aminopyridine moieties interact in different positions with the 
enzyme—Glu592 in the active site and the heme group. According to the X-ray crystals, there 
is a second 30 molecule binding also in the H
4
B site, specifically, and the pyridine moiety coor-
dinates with the Zn atom. This interaction does not take place in eNOS. Cellular permeability 
studies confirmed compound 30 as an interesting lead [59, 60].
Other symmetric double-headed aminopyridine series without charge groups were designed 
to contain a tail on the central aromatic ring. The objective is to achieve an interaction in the 
electronegative region in the catalytic site, since only the neuronal isoform has Asp597 in this 
region. Derivative 31 (Figure 10) was very potent (K
i
 = 56 nM) and highly selective over other 
isoforms (472-fold selective for eNOS and 239-fold for iNOS). This occurs because an electro-
positive functional group (Ciano group) is preferred near Asp597 in nNOS, explaining the 
selectivity of this compound [61].
Furthermore, double-headed inhibitors containing chiral linkers derived from natural amino 
acids were designed and synthesized. The best compound (Figure 10—32) showed high potency 
(K
i
 = 32 nM) against nNOS and a good selectivity profile (475-fold selective and 244-fold over 
eNOS and iNOS, respectively). The aminomethyl moiety was crucial in this compound, allow-
ing it to bind to the heme propionates in nNOS and leading to a high selectivity level [62].
2-Amino-4-methylpyridine groups with a chiral linker derived from proline were designed 
as selective nNOS inhibitors. They showed to be interesting as they can interact in a unique 
 orientation, what led to selectivity toward neuronal isoform. The aminopyridine groups 
 Figure 10. Double-headed nNOS inhibitors.
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interact with a Glu592 residue and the heme propionate in nNOS active site. In addi-
tion, the nitrogen from pyrrolidine linker is important to contribute to additional hydro-
gen bonds to the heme propionate, resulting in the most potent compound (K
i
 = 9.7 nM) 
(Figure 10—33). The finding that the isomer activities are different also reinforces the 
importance of chirality control of this kind of inhibitors and shows the dynamism of the 
target [63].
In addition, using chiral double-headed inhibitors, the α-amino-functionalized aminopyri-
dine derivative 34 (Figure 10) was more potent than other chiral compounds (K
i
 value of 24 
nM for nNOS, with 273-fold and 2822-fold selectivity against iNOS and eNOS, respectively). 
Structure-activity relationship studies reveal that the α-amino group close to the center phe-
nyl ring is crucial to stabilize the double-headed binding. Those studies also showed that 
by changing to aminomethyl group the potency is improved. The inhibitor is able to make 
H-bonds with both the H
4
B binding site and the propionate of the heme A-ring, which is 
essential to obtain selectivity over other isoforms. It is also important to note that the dis-
tinct electrostatic environments in different isoforms resulted in lower binding free energy in 
nNOS, which also can explain the potency difference [64].
The non-chiral double-headed thiophene-2-carboximidamide compound (Figure 10—35) 
exhibited an excellent inhibitory potency and selectivity (K
i
 = 5 nM; 540-fold and 340-fold 
selective over eNOS and iNOS, respectively). This compound also showed to be active in 
metastatic melanoma A375 cells, exhibiting EC
50
 values of 1.3 μM, better that of the drug cis-
platin (EC
50
 = 4.2 μM) [65].
2.3. Bacterial nitric oxide synthase (bNOS) inhibitors
Bacterial nitric oxide synthase (bNOS) is present in many Gram-positive microorganisms and 
has been described as part of their defense system against other species and the oxidative 
stress provoked by antibiotics through NO releasing. Therefore, bNOS inhibition can increase 
the antibiotic potential and be harmful to bacterial cell [66].
A screening showed that some known nNOS inhibitors can decrease significantly the percent 
survival of Bacillus subtilis WT treated with the antimicrobial acriflavine. This potential is 
consistent with NO production inhibition, as it decreases the bacterial resistance against that 
compound [67].
Exploring the potential of bNOS as a drug target, high selectivity levels are necessary to its 
inhibitors. In this context, the design of compounds that target the active and pterin-binding 
site has been considered an important strategy (Figure 11—36). These compounds are able to 
carry out an unexpected rotameric position of residue Arg247 in the active site, besides inter-
acting with the important residue of Glu243 from the same site [68].
In addition, with the goal to identify the differences among bNOS and other isoforms, crystal-
lography studies were performed using different inhibitor chemotypes. Researchers observed 
that Tyr706 from nNOS is conserved in bNOS (Tyr 357) and both have the same rotameric 
behavior, which is very different, compared with eNOS. This molecular feature can be useful 
to design new selective bNOS over eNOS inhibitor. Since the pharmacokinetic properties are 
very different between bNOS and nNOS, selectivity over the latter is not a trouble. However, 
Nitric Oxide Synthase - Simple Enzyme-Complex Roles228
due to steric hindrance in the tail end of thiophenecarboximidamide analogs, this scaffold can 
bind differently to bNOS comparatively to nNOS [69].
3. Clinical studies
A nonselective compound l-NMMA (Figure 12), also known as tilarginine, was evaluated 
clinically in Translational Research Investigating Underlying Disparities in Acute Myocardial 
Infarction Patients’ Health Status (TRIUMPH) study in North America and Europe with 
planned enrollment of 658 patients at 130 centers. The period of study was between January 
2005 and August 2006 (the study was terminated early). Using 1 mg/kg bolus and 5 h infu-
sion did not decrease the mortality rates in patients with refractory cardiogenic shock com-
plicating myocardial infarction despite an open infarct artery. Although the good results 
showed in phase II, it has failed in phase III [70, 71]. In another study l-NMMA resulted in 
no differences in mean arterial pressure (MAP) after 2 h compared with placebo group [72].
Evaluating another inhibitor, N(G)-nitro-l-arginine methyl ester (Figure 12—l-NAME), in 
the treatment of refractory cardiogenic shock, the death at 1 month was 27% in the l-NAME 
group versus 67% in the control group [73]. Additional studies have been performed to fur-
ther examination, concluding that TRIUMPH strongly indicated that nonselective NOS inhib-
itors are not clinically interesting [74].
 Figure 12. Clinically evaluated compounds.
 Figure 11. bNOS inhibitor.
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Recent phase I study in advanced solid tumors with the iNOS inhibitor ASP9853 (Figure 12) 
showed that the efficacy dose predicted in preclinical studies was not achieved due to overall 
toxicity limitations. In summary all these clinical information showed that the manipulation 
of the NOS pathway, with or without chemotherapy, appears to be more challenging than 
expected [75]. While designing new selective NOS inhibitors which should be highlighted, 
deeply studies to evaluate clinical benefits are also required.
4. Conclusions
Many scaffolds have been found to inhibit nitric oxide synthases. Some of them were presented 
in this chapter as promising for important therapeutic activity. It must be emphasized that the 
research about nitric oxide synthase inhibitors has expressively advanced thanks to the X-ray 
crystallographic studies of this enzyme. This helps the structure-based design approach toward 
the search for selective inhibitors of this enzyme and the comprehension of their mechanism of 
action. Notwithstanding, efforts have been made for imparting them with a drug-like profile.
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